XML 62 R52.htm IDEA: XBRL DOCUMENT v3.23.2
Collaborative arrangements and strategic partnerships - Summary of Revenue Recognized or Expense Incurred for Joint Ide-cel Development Efforts Related to Combined Unit of Accounting for its License and Vector Manufacturing of Ide-cel (Detail) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
Mar. 31, 2023
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2023
Jun. 30, 2022
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Research and development expense $ (59,980)   $ (64,557)   $ (128,226) $ (130,436)
Ide-cel Research And Development Services            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Research and development expense (5,652) $ (4,871) (5,463) $ (6,893) (10,523) (12,356)
Bristol-Myers Squibb | Ide-cel Research And Development Services            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Research And Development Expense Obligation Under Collaborative Arrangement (7,195) (9,461) (7,418) (8,118) (16,656) (15,536)
Reimbursements For Research And Development Expenses Under Collaborative Arrangement 1,543 $ 4,590 1,955 $ 1,225 6,133 3,180
Bristol-Myers Squibb | Outside of U.S. | Ide-cel license and manufacturing services | License and manufacturing services            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Revenue $ 2,988   $ 3,525   $ 9,111 $ 6,315